Abstract A critical step in the mechanism of action of inflammatory cytokines is the stimulation of sphingolipid metabolism, including activation of sphingosine kinase (SK), which produces the mitogenic and proinflammatory lipid sphingosine 1-phosphate (S1P). We have developed orally bioavailable compounds that effectively inhibit SK activity in vitro in intact cells and in cancer models in vivo. In this study, we assessed the effects of these SK inhibitors on cellular responses to tumor necrosis factor alpha (TNFa) and evaluated their efficacy in the dextran sulfate sodium (DSS) model of ulcerative colitis in mice. Using several cell systems, it was shown that the SK inhibitors block the ability of TNFa to activate nuclear factor kappa B (NFjB), induce expression of adhesion proteins, and promote production of prostaglandin E 2 (PGE 2 ). In an acute model of DSS-induced ulcerative colitis, SK inhibitors were equivalent to or more effective than Dipentum in reducing disease progression, colon shortening, and neutrophil infiltration into the colon. The effects of SK inhibitors were associated with decreased colonic levels of inflammatory cytokines TNFa, interleukin (IL)-1b, interferon gamma (IFN)-c, IL-6, and reduction of S1P levels. A similar reduction in disease progression was provided by SK inhibitors in a chronic model of ulcerative colitis in which the mice received 3-week-long cycles of DSS interspaced with week-long recovery periods. In the chronic model, immunohistochemistry for SK showed increased expression in DSS-treated mice (compared with water-treated controls) that was reduced by drug treatment. S1P levels were also elevated in the DSS group and significantly reduced by drug treatment. Together, these data indicate that SK is a critical component in inflammation and that inhibitors of this enzyme may be useful in treating inflammatory bowel diseases.
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Introduction
Inflammatory bowel disease (IBD) encompasses a group of disorders characterized by pathological inflammation of the lower intestine. Crohn's disease and ulcerative colitis are the most common forms of IBD, and whereas their etiologies are not fully elucidated, infectious and immunologic mediators have been clearly implicated. Studies on the development and treatment of IBD have been greatly facilitated by animal models that mimic the clinical and immunopathological disorders seen in humans [1] . From studies with these models, it is clear that the manifestations of IBD are dependent on cellular immune responses and inflammatory cytokines; however, the molecular mechanisms by which this occurs are not yet clearly defined. A common feature of immune activation in IBDs involves the influx of mast cells, monocytes, macrophages, and polymorphonuclear neutrophils into the epithelium of the colon, which results in amplification of the inflammation process, producing the clinical manifestations of the diseases [2] . This infiltration by granulocytes is accompanied by dramatic increases in levels of inflammatory cytokines in the colon [3] . Most prominently, tumor necrosis factor alpha (TNFa) has been shown to play a significant role in IBD, such that antibody therapy directed against this cytokine, i.e., Remicade, is a promising new treatment [4] . TNFa activates several processes that contribute to IBD, and it is necessary for both initiation and persistence of the Th1 response. For example, TNFa has been shown to act through the induction of nuclear factor kappa B (NFjB) [5] , which induces proinflammatory enzymes nitric oxide synthase (NOS) and cyclooxygenase-2 (COX-2) [6] . COX-2 plays a key role in IBD inflammation through its production of prostaglandins [7, 8] and oxidative stress such as that mediated by nitric oxide produced by NOS has also shown to exacerbate IBD inflammation [9] .
The mechanisms and effects of the sphingolipid metabolism have been the subjects of a growing body of scientific investigation, including analyses of its roles in inflammation [10] [11] [12] . Sphingomyelin is not only a structural component of cellular membranes but serves as the precursor for the potent bioactive lipids ceramide and sphingosine 1-phosphate (S1P). Ceramide is produced by hydrolysis of sphingomyelin in response to inflammatory stresses, including TNFa [13, 14] . Ceramide induces apoptosis in proliferating cells by a mechanism that remains to be elucidated [15, 16] , and it can be further hydrolyzed by ceramidase to produce sphingosine. Sphingosine is then rapidly phosphorylated by sphingosine kinase (SK) to produce S1P. Therefore, activation of ceramidase and SK by cytokines and growth factors leads to rapid increases in intracellular levels of S1P and depletion of ceramide levels. This situation promotes cell proliferation and inhibits apoptosis. Deregulation of apoptosis in phagocytes is an important component of the chronic inflammatory state in IBDs, and S1P has been shown to protect neutrophils from apoptosis in response to Fas, TNFa, and ceramide [17] . Similarly, apoptosis of macrophages is blocked by S1P [18] .
In addition to its role in regulating cell proliferation and apoptosis, S1P has been shown to have several other important effects on cells that mediate immune functions. Platelets, monocytes, and mast cells secrete S1P upon activation, promoting inflammatory cascades at the site of tissue damage [19, 20] . Activation of SK is essential for the signaling responses to TNFa, as its ability to induce adhesion molecule expression via activation of NFjB is mimicked by S1P and is blocked by the SK inhibitor dimethylsphingosine [14] . Similarly, S1P mimics the ability of TNFa to induce the expression of COX-2 and the synthesis of prostaglandin E 2 (PGE 2 ), and the knock-down of SK by RNA interference blocks these responses to TNFa but not S1P [21] . S1P is also a mediator of Ca 2+ influx during neutrophil activation by TNFa and other stimuli, leading to the production of superoxide and other toxic radicals [22, 23] .
Despite accumulating evidence for a pivotal role of SK in the regulation of inflammatory processes, pharmacological inhibition of SK is an untested means of preventing and/or treating IBDs. This is largely due to the heretofore lack of pharmacologically useful SK inhibitors. To overcome this problem, we recently identified nonlipid compounds that inhibit recombinant human SK and are cytotoxic toward human cancer cell lines [24, 25] . These compounds inhibit endogenous S1P formation in intact cells and demonstrate a high degree of selectivity for SK versus other lipid and protein kinases. Our lead SK inhibitors, 4-(2-[4-(4-chlorophenyl)thiazol-2-ylcarbamoyl]-vinyl)-2-methoxy-phenyl ester (ABC747080) and 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (ABC294640) (Fig. 1) , have excellent oral bioavailability and in vivo SK inhibitory activity in mice. Importantly, these SK inhibitors can be chronically administered to mice without systemic toxicity [26] . Therefore, ABC747080 and ABC294640 have been examined for their effects on TNFa-mediated cell activation and in murine models of ulcerative colitis. Data indicate that these compounds effectively inhibit TNFa-mediated responses, including activation of NFjB and induction of adhesion proteins and PGE 2 synthesis. Additionally, each compound suppresses disease progression in the in vivo models, suggesting that targeting SK is a viable new approach to the treatment of IBDs.
Materials and methods

Reagents
Unless otherwise noted, chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dipentum (Olsalazine), polyethylene glycol (PEG) 400, and dextran sulfate sodium (DSS) were from Cellteck Pharmaceutical (Rochester, NY, USA), J. T. Baker (Phillipsburg, NJ, USA), and MP Biomedicals, Inc. (Solon, OH, USA), respectively. SK inhibitors ABC294640 and ABC747080 were synthesized as follows:
ABC294640
Adamantane-1-carboxylic acid (45 g, 0.25 mol) was added to mixture of AlCl 3 (45 g, 0.34 mol) and Br 2 (450 g) at 0°C and stirred at 0-10°C for 48 h. The temperature of the mixture was then raised to 20°C for 5 h before the sample was poured onto 500 g of crushed ice, diluted with 300 ml of CHCl 3 , and decolorized with solid Na 2 S 2 O 5 . The aqueous phase was extracted twice with Et 2 O, and the combined organic phase was washed with H 2 O and extracted with 10% NaOH. The alkaline extraction was acidified with 2N H 2 SO 4 and provided 49 g of 3-bromoadamantane-1-carboxylic acid (yield = 75.7%). Over a 30-min period, 3-bromoadamantane-1-carboxylic acid (16.0 g, 61.7 mmol) in 50 ml of dry chlorobenzene at -10°C was added to 100 ml dry chlorobenzene containing 9.3 g (70 mmol) of AlCl 3 . The mixture was warmed to room temperature for 1 h and then heated to 90°C for 10 h. The mixture was then poured onto 200 g of crushed ice and then filtered to provide 14.2 g of 3-(4-chlorophenyl)adamantane-1-carboxylic acid (yield = 79.3%). 3-(4-chlorophenyl)adamantane-1-carboxylic acid was then reacted with 1,1 0 -carbonyldiimidazole to give an adamantanylcarbonylimidazole intermediate, which was reacted with 4-aminomethylpyridine in toluene to produce 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (ABC294640) with a yield of 92.6% and a melting point of 128-130°C. 1 Butyric acid 4-(2-carboxy-vinyl)-2-methoxy-phenyl ester (1.078 g, 4.08 mmol) was suspended in 12 ml of CH 2 Cl 2 , followed by addition of 2 M oxalyl chloride in 3 ml of CH 2 Cl 2 and 0.15 ml of DMF. After 30 min of stirring, the volatile components were removed in vacuo. The white residue was suspended in 20 ml of 1,4-dioxane, followed by the addition of 4-(4-chlorophenyl)thiazol-2-ylamine (861 mg, 4.08 mmol) in 0.5 ml of pyridine. The yellow suspension was stirred at its boiling point for 30 min, cooled to room temperature, and the solvent was removed in vacuo. The residue was partitioned in 50 ml of water and 100 ml of ethyl acetate, and the resulting organic phase was further sequentially washed with 0.5 N HCl, 5% NaHCO 3 and water. The organic solution was dried over Na 2 SO 4 3 H]S1P was measured, as previously described [24] .
Assay of NFjB activation
Human 293T embryonic kidney cells expressing the large T antigen, and a chromosomally integrated luciferase reporter construct regulated by six copies of the NFjB response element, were purchased from Panomics, Inc.
(Redwood City, CA, USA) and grown as recommended by the vendor. For experiments on TNFa-stimulation of NFjB activity, the cells were plated into 24-well culture plates and grown to confluence. The medium was then removed and replaced with serum-free medium for 16 h before 100 ng of TNFa/ml was added. After 6 h, the cells were washed and lysed, and the amount of luciferase was quantified using an assay kit from Promega Corporation (Madison, WI, USA) and a Perkin Elmer HTS 7000+ Bioassay plate reader in the luminescence mode.
Assay of adhesion protein expression
Human retinal endothelial cells were purchased from Cell Technologies (ACBRI181, Kirkland, WA, USA) and maintained in growth medium consisting of Minimum Essential Medium with D-valine supplemented with 20% fetal calf serum (Gibco, Rockville, MD, USA), 50 lg/ml of endothelial cell growth supplement (Vec Technologies, Rensslar, NY, USA), 16 U/ml heparin (Fisher Scientific, Pittsburg, PA, USA), minimum essential medium (MEM) vitamins and glutamine, and antibiotic/antimycotic (Gibco, Rockville, MD, USA). The cells were plated on a 25 cm 2 tissue culture flask coated with fibronectin at 2 lg/cm 2 and grown in a humidified incubator at 37°C. For experiments on TNFa signaling, the culture medium was replaced with fresh medium that lacked fetal calf serum for 24 h before the addition of 100 ng of TNFa/ml, and whole-cell lysates were prepared 6 h later. The protein concentrations in the samples were determined using the fluorescamine assay [27] with bovine serum albumin as the standard. Samples were normalized for equal amounts of protein per lane (100 lg), separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis, and electrotransferred to nitrocellulose membranes. The blots were then blocked and probed with antibodies to vascular cell adhesion molecule-1 (VCAM-1) (CBL206, Chemicon International, Temecula, CA, USA) or intracellular adhesion molecule-1 (ICAM-1) (sc-7891, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and developed with horseradish-peroxidase-conjugated secondary antibodies.
Assay of PGE 2 production
Human retinal endothelial cells were cultured as described above, and rat IEC6 intestinal epithelial cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum. In each case, the cells were plated into 24-well culture plates, allowed to grown to confluence, and then serum-starved for 8 h before the addition of buffer or 100 ng of TNFa/ml, and 10 lg/ml of ABC294640 or ABC747080. After 18 h, medium samples were removed, and PGE 2 levels were quantified using an ensyme-linked immunosorbent assay (ELISA) kit from Caymen Chemical (Ann Arbor, MI, USA).
Ulcerative colitis models
The acute model of DSS-induced ulcerative colitis utilized male C57BL/6 mice, which were provided standard rodent diet and water ad libitum. After their acclimation, the animals were randomly divided into groups of five or six for DSS-(40,000 MW) and drug treatments. SK inhibitors were dissolved in PEG (400 average MW) and given once-daily by oral gavage in a volume of 0.1 ml per dose. Dipentum (Olsalazine Sodium) was used as a positive control. Dipentum is US Food and Drug Administration-approved anticolitis drug whose active ingredient is metabolized to 5-aminosalicylic acid in vivo. The mice were treated as follows:
Group Dextran sulfate sodium Oral treatment (once daily on days 0-6) The Disease Activity Index (DAI) (detailed below), which monitors weight loss, stool consistency, and blood in the stool as a measure of disease severity, was scored for each animal on days 4-6. On day 7, the mice were sacrificed by CO 2 asphyxiation followed by cervical dislocation, and the entire colon was removed and measured to the nearest 0.1 cm. The colon was then divided into thirds and used for histologic and biochemical studies described below.
A chronic 35-day model of IBD was used to evaluate the effectiveness of the SK inhibitors in mice that experienced multiple cycles of DSS-induced inflammation. The chronic model is similar to the acute model, except that the DSS concentration in the drinking water is lower and animals that receive periodic exposure to DSS (DSS on days 1-7, water on days 8-13, DSS on days 14-21, water on days 22-27, and then DSS until the completion of the study on day 35). In these experiments, treatment of mice with an SK inhibitor or Dipentum began on day 28 and continued daily until study completion. The DAI index was monitored every other day until day 28 and then daily until day 35.
Disease Activity Index (DAI)
The DAI was calculated for each animal as described by Fitzpatrick et al. [28] according to the following scoring system: With this scoring system, the DAI is calculated by scoring each animal for weight loss, stool consistency, and blood in the stool and then dividing the total score by three. For example, an animal that lost 11% of its body weight (score of 3) with evidence of loose stool (score of 2) plus gross rectal bleeding (score of 4) would have a calculated DAI of 3.
Histology score
The distal one third (*2.5 cm) of the colon was transected, pinned open, and rinsed with phosphate-buffered saline (PBS), and the incidence of gross inflammation (continuous areas of redness) was recorded. The tissue was then fixed with formalin overnight, followed by embedding in paraffin, sectioning, and staining with hematoxylin and eosin (H&E). The sections were microscopically examined for histopathologic changes using the following scoring system: Histology score was determined by multiplying the percent involvement for each of the three following histological features by the percent area of involvement [29] [30] [31] [32] . Therefore, the minimal score is 0 and the maximal score is 40.
Myeloperoxidase assay
Mucosal myeloperoxidase (MPO) activity was determined as a measure of granulocyte and monocytes infiltration into the colon. The middle one third of the colon was removed and snap frozen in a methanol/dry ice bath and stored at -80°C until time of assay. The colon was then thawed and homogenized in 10 volumes (w/v) of cold PBS. The homogenate was then centrifuged at 22,000 g for 15 min, and the resulting pellet was resuspended and assayed for MPO by quantifying the metabolism of tetramethylbenzidine as described by Fitzpatrick et al. [28] .
Sphingosine 1-phosphate assay
Samples of each colon were homogenized as indicated above, and plasma samples, taken at the time of sacrifice, were extracted with ethyl acetate/isopropanol/water (60/30/ 10, by volume). The organic phase, containing the sphingolipids, was dried under nitrogen and then dissolved in Calibration curves were generated by plotting the area ratios of the synthetic standards for each sphingolipid and were used to determine the absolute amounts of sphingosine and S1P in the serum and colon samples from control and SK-inhibitor-treated mice.
Cytokine assays
Supernatants for the homogenates of each colon were used to determine the levels of TNFa, interleukin (IL)-1b, interferon gamma (IFN-c), IL-6, and IL-10 using Luminex assays performed by the Cytokine Core Laboratory at the University of Maryland, Baltimore.
Immunohistochemical analysis of SK expression in colon
Expression of SK in the colons from the chronic DSS model was assessed. Briefly, sections were deparaffinized in xylene and rehydrated in a series of ethanol dilutions. Sections were permeabilized in 0.5% Triton X-100 in PBS and boiled for 10 min in 10 mM sodium citrate buffer for antigen retrieval. Slides were then incubated 10 min in 3% hydrogen peroxide to quench endogenous peroxidase. After washing in PBS, sections were blocked for 1 h with the appropriate reagent from the VECTASTAIN ABC Kit (Vector Laboratories Inc.) used for the remaining steps. Sections were then incubated for 30 min at room temperature with primary SK antibody (rabbit polyclonal AB675; Biosynthesis Inc, Lewisville, TX, USA, raised against a seven amino acid peptide evaluated to be exclusive to only SK) followed by PBS washes and 30-min incubation with diluted biotinylated secondary antibody and then 30-min incubation with diaminobenzidine (DAB) reagent. Sections were lightly counterstained with hematoxylin, rehydrated, and mounted for analysis by bright-field microscopy.
Data analyses
Differences among treatment groups were analyzed by two-tailed unpaired t test analyses, with a difference of P \ 0.05 considered statistically significant.
Results
Sphingosine kinase activity in intestinal epithelial and endothelial cells
To confirm that SK is present in endothelial cells, we previously demonstrated its expression in bovine, rat, and human endothelial cells by Western blot analyses using polyclonal antibodies that cross-react with SK from multiple species [33] . Each of several preparations of human endothelial cells contained high amounts of SK protein, demonstrating that these cells consistently express SK.
To evaluate the effects of compounds on the activity of SK in intact cells, we developed a cell-based assay in which the phosphorylation of exogenously added [
3 H]sphingosine to [ 3 H]S1P by endogenous SK can be quantified [24] . The assay is patterned after our in vitro SK assay in which [ 3 H]sphingosine and [
3 H]S1P are separated by extraction, and levels of both species are determined by scintillation counting. We used a number of cell lines in this assay to confirm that the SK inhibitors are active in multiple intact cell systems. Most relevant to IBD, we demonstrated that the lead SK inhibitors reduce cellular levels of S1P synthesis in human endothelial cells and rat IEC6 cells (Fig. 2) . ACB294640 and ABC747080 each caused dose-dependent suppression of SK activity in each of the cell types, with the endothelial cells being somewhat more sensitive than the epithelial cells.
In vitro effects of SK inhibitors on signaling by TNFa
The effects of the two lead SK inhibitors on responses of human endothelial cells to TNFa were characterized. The excellent aqueous solubility of ABC294640 allowed it to be evaluated in an NFjB reporter cell line (Fig. 3) . Fibroblasts transfected with an NFjB response element linked to luciferase produce high levels of the enzyme upon exposure to TNFa. Activation of NFjB by TNFa was dosedependently suppressed by the SK inhibitor ABC294640, with an IC 50 of approximately 20 lM, which corresponds well to its potency for inhibiting S1P production in cells. The sensitivity of these cells to organic solvents precluded similar studies with ABC747080, which is typically solubilized with DMSO or EtOH for in vitro studies.
Western boot analyses were conducted with human endothelial cells to evaluate the effects of the SK inhibitors on signaling proteins known to be regulated by TNFa. In these experiments, the cells were serum-starved for 24 h and then exposed to TNFa (100 ng/ml) for 6 h. Cell lysates from treated cells were assayed for adhesion molecules ICAM and VCAM. As indicated in Fig. 4 , TNFa caused marked increases in the expression levels of adhesion proteins involved in leukocyte recruitment, including ICAM-1 and VCAM-1. These effects of TNFa were attenuated by treating the cells with either ABC294640 or ABC747080, such that the induction of both proteins was completely abrogated by 25 lM ABC294640.
To determine the effect of the SK inhibitors on COX-2 activity, an ELISA assay was used to measure PGE 2 production by IEC6 rat intestinal epithelial cells and human endothelial cells treated with TNFa. Exposure of either type of cell to TNFa resulted in marked increases in COX-2 activity, measured as the production of PGE 2 (Fig. 5) . This induction of COX-2 activity by TNFa was strongly suppressed by ABC294640 or ABC747080. In vivo effects of SK inhibitors in DSS models of ulcerative colitis
The acute model of DSS-induced ulcerative colitis utilized male C57BL/6 mice, which were randomly divided into groups of five or six for DSS and drug treatments. SK inhibitors were dissolved in PEG 400 and given once daily by oral gavage in a volume of 0.1 ml per dose. Dipentum, an FDA-approved anticolitis drug whose active ingredient, olsalazine, is converted to 5-aminosalicylic acid in vivo, was used as a positive control. The mice were given normal drinking water or 2% DSS and treated orally with an SK inhibitor or Dipentum at a dose of 50 mk/kg daily, and the DAI, which monitors weight loss, stool consistency, and blood in the stool as a measure of disease severity, was scored for each animal on days 4-6. Animals receiving normal drinking water and PEG as a solvent control had very low DAIs throughout the experiment (Fig. 6) . Exposure of the mice to DSS in their drinking water markedly induced IBD symptoms, including weight loss and the production of loose, bloody stools. The intensity of the disease progressively increased from day 4 to the time the mice were sacrificed on day 6. Treatment of the animals receiving DSS with ABC294640, ABC747080, or Dipentum reduced the intensity of IBD manifestations, most dramatically on day 6. SK inhibitors and Dipentum were essentially equivalent in their abilities to reduce the DAI of mice receiving DSS. It should be noted that this acute model produces rapid and dramatic symptoms of IBD, making it a very stringent assay for drug testing.
On day 6, the animals were sacrificed by cervical dislocation, and the entire colon was measured to assess shortening due to scarring and damage and then fixed, sectioned, and examined histologically on a blinded basis. Compared with the water control group, the colons of mice treated with DSS and PEG were significantly shortened (Fig. 7) . DSS-treated mice that were also treated with ABC294640, ABC747080, or Dipentum had colons of intermediate length, indicating substantial protection by the drugs. Again, the response to either of the SK inhibitors was at least as good as that of mice treated with Dipentum.
Histological examination of colon sections from the various treatment groups were consistent with the DAI endpoint, revealing marked damage in the DSS-alone group that was reduced or negated in the SK-inhibitortreated animals (Fig. 8) . Panel a shows a normal colon from a water-treated control animal, whereas panel b shows a severely inflamed and damaged colon from a DSS-treated animal. Numerous neutrophils were present throughout the As a quantifiable measure of damage, the colons were graded for their histology score, which is based on inflammation severity, inflammation extent, crypt damage, and percentage of surface area demonstrating the characteristic. These morphologies were scored on a blinded basis. As indicated in Fig. 9 , animals receiving DSS in their drinking water had substantially higher histology scores (representing moderate-to-severe IBD) than animals receiving normal drinking water (which had some mild inflammation, possibly due to the PEG vehicle). As with the other assays, the histology scores of mice given an SK inhibitor or Dipentum were consistently lower than the DSS-alone animals, although not all animals were fully protected. DAI scores and histology scores correlated well for individual animals (data not shown), confirming the DAI score as an excellent indicator of colon inflammation and damage.
Myeloperoxidase activity, which is reflective of neutrophil influx into the colon, is often used as a measure of inflammation and was assayed in the colons of the mice Fig. 7 Effects of sphingosine kinase (SK) inhibitors and Dipentum on colon length in the acute dextran sulfate sodium (DSS)-colitis model. Mice from the experiment described in Fig. 6 were sacrificed on day 6, and the colon was harvested from each animal and measured. Data represent the mean ± standard deviation colon length from the DSS-colitis studies. As indicated in Fig. 10 , MPO activity was highly elevated in the DSS-alone animals compared with water-treated controls. The increase in MPO activity was markedly attenuated in mice receiving daily doses of ABC294640, ABC747080, or Dipentum. This reduction in the activity of the neutrophil marker is consistent with the decreased occurrence of granulocytes observed in the H&E-stained colon sections (Fig. 8) . Therefore, the level of colonic MPO appears to be an excellent biomarker for the extent of tissue infiltration by inflammatory leukocytes. Several cytokines involved in inflammation were measured by the Cytokine Core Laboratory at the University of Maryland, Baltimore, using the Luminex 100 system that allows quantification of multiple cytokines and growth factors in a small sample volume. We examined the Th1 cytokine IFN-c, the regulatory IL-10 cytokine, as well as the macrophage-derived proinflammatory cytokines TNFa, IL-1b, and IL-6 in colon samples from mice in the DSS model of colitis. Figure 11 depicts the results of these assays and indicates that DSS treatment promoted accumulation of all of the cytokines in the colon. Importantly, elevations of all of proinflammatory proteins, i.e., IFN-c, IL-1b, IL-6, and TNFa, were attenuated in mice treated with either an SK inhibitor or Dipentum. Conversely, levels of the anti-inflammatory cytokine IL-10 were not suppressed by SK inhibitors.
As a final measure of the effects of SK inhibitors in this acute model, S1P levels were assayed in the colons of DSStreated animals using a liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. This technique allows us to examine correlations between biologic activity and changes in S1P levels in animals treated with SK inhibitors. Colon samples from animals from the DSScolitis experiments were homogenized in cold PBS, spiked with internal standards (C 17 analogs of sphingosine and S1P), and processed by liquid-liquid extraction. Ratios of analyte to internal standard for each sphingolipid were determined. S1P levels were markedly higher in colons from DSS-treated mice compared with water-treated controls (Fig. 12) . Importantly, animals treated with either ABC294640 or ABC747080 had markedly lower levels of colonic S1P than did DSS-alone samples.
Chronic model
A 35-day model of IBD was used to evaluate the effectiveness of the SK inhibitors in mice that experience multiple cycles of DSS-induced inflammation. This chronic model was similar to the acute model, except that the DSS concentration in the drinking water was lower and animals received periodic exposure to DSS (DSS on days 1-7, water on days 8-13, DSS on day 14-21, water on days 22-27, and then DSS until the completion of the study on day 35). In these experiments, treatment of the mice with an SK inhibitor or Dipentum began on day 28 and continued daily until study completion. The DAI index was monitored every other day until day 28 and then daily until day 35. Animals were sacrificed on day 35, and changes in colon length and cytokine profiles were measured.
As previously described by others, cyclic exposure of mice to DSS in their drinking water caused reversible increases in the DAI (Fig. 13) . Treatment of the mice with ABC294640, ABC747080, or Dipentum during the third exposure to DSS significantly suppressed the increase in DAI experienced by the control mice (P \ 0.001 for all three compounds on day 35). Fig. 9 Effects of sphingosine kinase (SK) inhibitors and Dipentum on the colon histology score in the acute dextran sulfate sodium (DSS)-colitis model. Mice from the experiment described in Fig. 6 were sacrificed on day 6, and the colon was harvested from each animal and the histology score was determined. Values represent the mean ± standard deviation for five to six mice per group Colon lengths of DSS-treated mice were significantly shorter than the water-treated control animals (4.9 ± 0.2 cm vs. 7.8 ± 0.3 cm), reflecting inflammation-induced scarring. As in the acute model, the colons of animals treated with ABC294640, ABC747080, or Dipentum were of intermediate length (6.2 ± 0.2, 5.8 ± 0.1, and 6.1 ± 0.2 cm, respectively). This is a significant finding, as the animals were untreated for the first and second DSS cycles. Therefore, suppression of inflammation-induced colon contraction can be reversed by effective anti-IBD drugs.
Immunohistochemistry revealed that SK expression was present in low levels in the colons of control, non-DSStreated mice. SK expression was elevated in the colons of DSS-treated mice compared with water controls, with this expression clearly reduced in DSS mice also receiving compound ABC294640 (Fig. 14) .
Sphingosine 1-phosphate levels in the colons of chroniccolitis-model mice were assessed in an identical manner as described for the acute model and revealed results similar to those in the acute model, with elevated S1P levels in DSS-alone-treated mice compared with water-treated controls (Fig. 15) . Treatment with compounds ABC29460 and ABC747080 (oral 50 mg/kg daily; 7 days prior to sacrifice) resulted in significant reductions of S1P levels (Fig. 15) .
The levels of the proinflammatory cytokines TNFa, IL-1b, IFN-c, and IL-6 were substantially increased in the colons of mice treated chronically with DSS; whereas, the level of IL-10 was unchanged (Fig. 16 ). Mice treated with ABC294640 during the final DSS cycle had reduced levels of the proinflammatory cytokines, whereas animals treated with ABC747080 or Dipentum expressed cytokine profiles equivalent to the DSS-alone group. This may reflect the presence of high numbers of resident immune cells in the colons of mice exposed chronically to DSS. However, the elevation in cytokine levels in SK-inhibitor-treated mice did not result in increased DAI or colon shortening, indicating that signaling induced by the inflammatory cytokines had been blocked.
For comparison, levels of the same cytokines in serum of mice at the time of sacrifice were also determined. As indicated in Fig. 17 , circulating levels of these cytokines were markedly lower than colonic levels, reflecting the local inflammation in this model. DSS increased circulating levels of IL-1b, IFN-c, IL-6, and IL-10, whereas TNFa remained below the detection limit of the assay. None of the test compounds affected circulating levels of IL-1b or IFN-c; Fig. 12 Effects of sphingosine kinase (SK) inhibitors on sphingosine 1-phosphate (S1P) levels in colons of animals in the dextran sulfate sodium (DSS)-colitis model. Colon samples from mice described in Fig. 6 were extracted and assayed for levels of S1P by liquid chromatography tandem mass spectroscopy (LC-MS/MS) as described in the ''Materials and methods'' section. Values represent the mean ± standard deviation for four to five samples per group however, both ABC294640 and Dipentum reduced the serum level of IL-6. Therefore, serum levels of IL-6 may be a useful pharmacodynamic marker for the anti-inflammatory effects of SK inhibitors during clinical testing.
Discussion
The SK inhibitors described in this report were originally envisioned to provide new antiproliferative and proapoptotic agents for the treatment of cancer. However, recent recognition of the importance of sphingolipid metabolism in mediating the effects of inflammatory cytokines promoted our exploration of the effects of these compounds using in vitro and in vivo models of IBD. Overall, these results indicate that the SK inhibitors under development are promising new agents for evaluation in the clinical treatment of IBDs. In vitro experiments showed that the SK inhibitors attenuate many of the effects of TNFa, including expression of VCAM and ICAM. This is interesting, as all three of these proteins are current targets for IBD treatment, as Remicade (a TNFa scavenger) is on the market, Tysabri (which blocks VCAM-1) is in phase III trials for Crohn's disease, and Alicaforsen (an antisense inhibitor of ICAM-1) recently completed a successful phase II trial. Therefore, the combined mechanistic data support the hypothesis that SK inhibitors are likely to be effective for clinically preventing and/or treating IBD mediated by inflammatory cytokines. Evidence to support the advancement of SK inhibitors toward the clinic was provided in both acute and chronic mouse models of ulcerative colitis. In both models, the DAI was reduced by SK inhibitors to a similar, or lower, level than the positive control drug, Dipentum, which is currently on the market for mild-to-moderate IBDs. Treatment of DSS-exposed mice with an SK inhibitor resulted in colons that were longer and less damaged as determined by histological evaluation. Reflecting this protection, a broad spectrum of inflammatory mediators, including S1P, NFjB, TNFa, VCAM-1, ICAM-1, COX-2, myeloperoxidase activity, IL-1b, IFN-c, and IL-6, were favorably modulated by treatment with an SK inhibitor. The efficacy of these findings provides further evidence that the anti-IBD activity of the compounds under study is linked to SK inhibition and decreased S1P formation in the colons of mice.
The findings of elevated SK and S1P levels in the colons of mice experiencing ulcerative colitis are novel and lend further evidence that these agents play important roles in the etiology of IBD. Interestingly, colon samples from patients with Crohn's disease demonstrate similar elevations of SK expression (unpublished observations), indicating that this pathway is also aberrantly activated in human IBD. Studies are underway to determine the relationships between SK overexpression, IBD severity, and response to chemotherapy. A model for the roles of sphingolipid metabolites in the pathology of IBDs is summarized in Fig. 18 . A combination of events occurs in the intestinal endothelial and epithelial cells and recruited mast cells, macrophages, and neutrophils. Early in the disease, immunologic reactions or other activating signals promote the release of inflammatory cytokines, particularly TNFa, from macrophages and mast cells. Several studies have shown that the actions of TNFa are mediated through its activation of S1P production. For example, TNFa induces S1P production in endothelial cells [14, 34] , hepatocytes [35] , neutrophils [36] , monocytes [37] , fibroblasts [21] , and lung adenocarcinoma cells [21] by activation of sphingomyelinase, ceramidase, and SK. S1P is a central player in the pathway, as it has pleiotropic actions on mucosal epithelial cells, macrophages, mast cells, and neutrophils. Within the intestinal endothelial cells, S1P activates NFjB, thereby inducing the expression of adhesion molecules, COX-2 resulting in PGE 2 synthesis, and NOS producing nitric oxide. Together, these chemoattractants and the adhesion molecules promote neutrophil infiltration into the mucosa. SK has been directly demonstrated to play a significant role in the recruitment and function of these cells [22, 38] . At the same time, S1P activates the neutrophils, resulting in the release of oxygenfree radicals that further inflame and destroy epithelial tissue. Similarly, S1P promotes activation and degranulation of mast cells.
According to this model, two major targets for new anti-IBD therapies can be defined: TNFa and S1P. A great deal of effort has focused on developing anti-TNFa agents, leading to the introduction of Remicade and related agents to the clinic. The use of SK inhibitors as anti-IBD agents has not been previously addressed, largely because of the heretofore lack of potent, specific SK inhibitors that are pharmacologically active. We have now identified novel small-molecule inhibitors of SK that have in vivo anti-IBD activity. We believe that these compounds will be useful for the treatment and/or prevention of IBDs by blocking the production of S1P in response to TNFa. This will prevent the deleterious activation of neutrophils, macrophages, and mast cells, as well as prevent neutrophil infiltration into the mucosa. Overall, it is clear that S1P is a critical component in inflammation, making SK an excellent target for the development of new anti-inflammatory drugs for the treatment of ulcerative colitis and/or Crohn's disease.
